Preclinical properties and human in vivo assessment of 123I-ABC577 as a novel SPECT agent for imaging amyloid-β

Brain

Volumn 139, Issue 1, 2016, Pages 193-203

  Maya, Yoshifumi ^a   Okumura, Yuki ^a   Kobayashi, Ryohei ^a   Onishi, Takako ^a   Shoyama, Yoshinari ^a   Barret, Olivier ^b   Alagille, David ^b   Jennings, Danna ^b   Marek, Kenneth ^b   Seibyl, John ^b   Tamagnan, Gilles ^b   Tanaka, Akihiro ^a   Shirakami, Yoshifumi ^a  

^a Nihon Medi Physics   (Japan)

^b Molecular Neuroimaging   (United States)

Author keywords

Alzheimer's disease; Amyloid ; Imaging; Radiotracer; Single photon emission computed tomography

Indexed keywords

ABC 577 I 123; AMYLOID BETA PROTEIN; FLORBETAPIR F 18; IMIDAZOPYRIDINE DERIVATIVE; IODINE 123; TRACER; UNCLASSIFIED DRUG; 123I-ABC577; BIOLOGICAL MARKER; IMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTERIOR CINGULATE; ARTICLE; AUTOPSY; AUTORADIOGRAPHY; BINDING AFFINITY; BINDING ASSAY; BRAIN CORTEX; BRAIN TISSUE; CASE REPORT; CEREBELLUM; CLINICAL STUDY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG RETENTION; DRUG UPTAKE; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR IMAGING; NEUROIMAGING; NONHUMAN; OCCIPITAL CORTEX; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRECLINICAL STUDY; PRIORITY JOURNAL; RADIOIODINATION; RAT; RETINA IMAGE; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TEMPORAL CORTEX; VERY ELDERLY; WHITE MATTER; YOUNG ADULT; ANIMAL; CASE CONTROL STUDY; FUNCTIONAL NEUROIMAGING; METABOLISM; PROCEDURES; SYNTHESIS; TISSUE DISTRIBUTION;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BIOMARKERS; CASE-CONTROL STUDIES; CEREBRAL CORTEX; FEMALE; FUNCTIONAL NEUROIMAGING; HUMANS; IMIDAZOLES; MALE; PYRIDINES; RATS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YOUNG ADULT;

EID: 84964649273     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv305     Document Type: Article

References (34)

1. Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG, et al. Clinical core of the Alzheimer's Disease neuroimaging initiative: progress and plans. Alzheimer's Dement 2010;6:239-46.
2. Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-βeta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 2011;10:424-35.
3. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795-804.
4. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59.
5. Chen CJ, Bando K, Ashino H, Taguchi K, Shiraishi H, Shima K, et al. In vivo SPECT Imaging of Amyloid-beta Deposition with Radioiodinated Imidazo[1, 2-a]Pyridine Derivative DRM106 in a Mouse Model of Alzheimer's Disease. J Nucl Med 2015;56:120-6.
6. Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, et al. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med 2009;50:1887-94.
7. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011;305:275-83.
8. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112-7.
9. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184-5.
10. Huijbers W, Mormino EC, Schultz AP, Wigman S, Ward AM, Larvie M, et al. Amyloid-beta deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. Brain 2015;138(Pt 4):1023-35.
11. Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects. J Nucl Med 2012;53:378-84.
12. Kung HF, Kung MP, Zhuang ZP, Hou C, Lee CW, Plossl K, et al. Iodinated tracers for imaging amyloid plaques in the brain. Mol Imaging Biol 2003;5:418-26.
13. Kung MP, Weng CC, Lin KJ, Hsiao IT, Yen TC, Wey SP. Amyloid plaque imaging from IMPY/SPECT to AV-45/PET. Chang Gung Med J 2012;35:211-8.
14. Mathis CA, Mason NS, Lopresti BJ, Klunk WE. Development of positron emission tomography beta-amyloid plaque imaging agents. Semin Nucl Med 2012;42:423-32.
15. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003;46:2740-54.
16. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr. Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement 2011;7:263-9.
17. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-52.
18. Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 2009;50:1251-9.
19. Newberg AB, Wintering NA, Plossl K, Hochold J, Stabin MG, Watson M, et al. Safety, biodistribution, and dosimetry of 123I-IMPY: A novel amyloid plaque-imaging agent for the diagnosis of Alzheimer's disease. J Nucl Med 2006;47:748-54.
20. Nyberg S, Jonhagen ME, Cselenyi Z, Halldin C, Julin P, Olsson H, et al. Detection of amyloid in Alzheimer's disease with positron emission tomography using [11C]AZD2184. Eur J Nucl Med Mol Imaging 2009;36:1859-63.
21. Ono M, Cheng Y, Kimura H, Watanabe H, Matsumura K, Yoshimura M, et al. Development of novel 123I-labeled pyridyl benzofuran derivatives for SPECT imaging of beta-amyloid plaques in Alzheimer's disease. PLoS One 2013;8:e74104.
22. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer's Dement 2013;9:63-75, e2.
23. Qu W, Kung MP, Hou C, Benedum TE, Kung HF. Novel styrylpyridines as probes for SPECT imaging of amyloid plaques. J Med Chem 2007;50:2157-65.
24. Reiman EM, Langbaum JB, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N, et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimer's Dis 2011;26(Suppl 3):321-9.
25. Roberson ED, Mucke L. 100 years and counting: prospects for defeating Alzheimer's disease. Science 2006;314:781-4.
26. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008;7:129-35.
27. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007;68:1718-25.
28. Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med Technol 2013;41:11-8.
29. Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, et al. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med 2014;275:251-83.
30. Sperling RA, Mormino E, Johnson K. The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron 2014;84:608-22.
31. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement 2011;7:280-92.
32. Sperling RA, Laviolette PS, O'Keefe K, O'Brien J, Rentz DM, Pihlajamaki M, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009;63:178-88.
33. Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010;68:319-29.
34. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013;12:357-67.